| Literature DB >> 35568823 |
Bo Tang1,2, Gengmei Gao1,2, Shanping Ye1, Dongning Liu1, Qunguang Jiang1, Junhua Ai1, Xiong Lei1, Jun Shi3, Taiyuan Li4.
Abstract
BACKGROUND: Urogenital dysfunction is recognized as a serious complication affecting patient quality of life after rectal cancer surgery to treat rectal cancer; however, the studies focus on the urogenital function after robot-assisted rectal cancer surgery compared to laparoscopic surgery are limited.Entities:
Keywords: Da Vinci robot; Laparoscopic; PANP; Rectal cancer; TME; Urogenital function
Mesh:
Year: 2022 PMID: 35568823 PMCID: PMC9107708 DOI: 10.1186/s12893-022-01592-1
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Patient and procedure characteristics of two groups
| Variables | R-TME (n = 38) | L-TME (n = 39) | P value |
|---|---|---|---|
| Age (years) | 47.75 ± 9.62 | 46.01 ± 9.37 | 0.424 |
| BMI (kg/m2) | 21.34 ± 2.67 | 22.03 ± 2.51 | 0.246 |
| ASA score n(%) | 0.301 | ||
| I | 22(57.9%) | 27(69.2%) | |
| II | 16(42.1%) | 12(30.8%) | |
| Tumor location (cm) | 6.33 ± 2.21 | 5.82 ± 2.43 | 0.339 |
| Neoadjuvant therapy n (%) | 9(23.7%) | 11(28.2%) | 0.651 |
| Operation method n (%) | 0.591 | ||
| LAR | 32(84.2%) | 31(79.5%) | |
| APR | 6(15.8%) | 8(20.5%) | |
| Stoma n (%) | 8(21.1%) | 7(17.9%) | 0.731 |
| Tumor differentiation n (%) | 0.826 | ||
| Well | 5(13.2%) | 6(15.4%) | |
| Moderate | 25(65.8%) | 23(59.0%) | |
| Poor | 8(21.0%) | 10(25.6%) | |
| Tumor stage n (%) | 0.367 | ||
| T1 | 3(5.3%) | 3(7.7%) | |
| T2 | 10(26.3%) | 7(17.9%) | |
| T3 | 22(57.9%) | 24(61.5%) | |
| T4 | 3(7.9%) | 5(12.8%) | |
| Nodal stage n (%) | 0.761 | ||
| N0 | 28(73.7%) | 30(76.9%) | |
| N1 | 7(18.4%) | 6(15.4%) | |
| N2 | 3(7.9%) | 3(7.7%) | |
| Adjuvant therapy n (%) | 13(34.2%) | 15(38.5%) | 0.114 |
BMI body mass index, ASA American Society of Anesthesiologists, LAR low anterior resection, APR abdominoperineal resection
IPSS between the two groups
| R-TME (n = 38) | L-TME (n = 39) | P value | |
|---|---|---|---|
| Baseline | 7.12 ± 3.05 | 7.04 ± 2.48 | 0.880 |
| 3Mon | 11.65 ± 2.93 | 12.21 ± 2.62 | 0.379 |
| 6Mon | 7.82 ± 2.25 | 9.95 ± 3.01 | 0.006 |
| 12Mon | 7.62 ± 2.5 | 9.12 ± 2.64 | 0.012 |
IPSS International Prostate Symptom Score, TME total mesorectal excision
Fig. 1IPSS between the two groups, *indicated significant difference between two groups at the time point
IIEF-5 scores between the two groups
| R-TME (n = 38) | L-TME (n = 39) | P value | |
|---|---|---|---|
| Baseline | 22.23 ± 3.65 | 22.93 ± 3.82 | 0.414 |
| 3Mon | 14.87 ± 3.27 | 13.92 ± 3.62 | 0.231 |
| 6Mon | 18.55 ± 3.45 | 16.75 ± 3.26 | 0.021 |
| 12Mon | 21.22 ± 3.06 | 19.95 ± 3.03 | 0.071 |
IIEF-5 International Index of Erectile Function
Fig. 2IIEF-5 scale between the two groups, *indicated significant difference between two groups at the time point